Lennerz V*, Gross S*, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein AF, Gnad-Vogt U*, Zieschang J, Forssmann U*, Woelfel T*, Kaempgen E*. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother. 2014 Feb 2. [Epub ahead of print] *equal contributions
Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, Fatho M, Lennerz V, Wölfel T, Hölzel M, Tüting T. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490(7420):412-6.
Graf C, Heidel S, Tenzer S, Radsak MP, Solem FK, Britten CM, Huber C, Fischer T, Wölfel T. A neoepitope generated by a FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells. Blood 109:2985-2988, 2007
Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102:246-253, 2005.
Herr W, Linn B, Leister N, Wandel E, Meyer zum Büschenfelde KH, Wölfel T. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor a spots in response to peptide antigens. J Immunol Methods 203:141-152, 1997
Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Büschenfelde KH, Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1284, 1995
Wölfel T., Klehmann E., Müller C., Schütt KH, Meyer zum Büschenfelde KH, Knuth A. Lysis of human melanoma cells by autologous cytolytic T cell (CTL) clones: Identification of HLA-A2 as a restriction element for three different antigens. J Exp Med 170 :797-810, 1989.